Search "what is Selank" and you will get a fairly consistent answer: a Russian anti-anxiety peptide, a "nootropic", a calmer cousin of benzodiazepines. That description is not wrong, but it describes maybe half of the published Selank research. The other half — the half that came first — is immunological. Selank was designed from a fragment of a human antibody, and a substantial body of its animal work measures interferon genes, spleen cytokine expression and survival in influenza-infected mice, not Hamilton anxiety scores.

That gap matters for Australian readers for two reasons. First, it tells you what kind of compound this actually is at a mechanistic level. Second, almost none of the immune work has ever been tested in a human being — which makes the immune-support claims that occasionally attach to Selank considerably weaker than the (already small) anxiety evidence. Here is what the Selank research shows, what it does not, and where the compound sits under Australian rules.

What is Selank, and where did it come from?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin — a naturally occurring tetrapeptide cleaved from the heavy chain of human immunoglobulin G, long studied for stimulating macrophage phagocytosis. Tuftsin is an immune molecule by origin and function. Researchers at the Institute of Molecular Genetics in Moscow extended it at the C-terminus with Pro-Gly-Pro, which slows enzymatic breakdown, and the resulting peptide was developed as an anxiolytic.

So the anxiety framing is a downstream application of an immune peptide backbone, not the starting point. You can see the inheritance in the research record: papers describe Selank as having "nootropic, anxiolytic and antiviral" activity in the same sentence.

More background on the compound sits on our Selank profile page, alongside the rest of the peptides library.

The Selank immune research most pages skip

Influenza in mice and cell culture

The most-cited immune study tested Selank against influenza A/Aichi/2/68 (H3N2). In cell culture, adding Selank 24 hours before inoculation — a preventive schedule — suppressed viral reproduction, and in mice the preventive schedule produced the highest survival. Mechanistically, the authors reported that Selank induced interferon-alpha gene expression without measurable change in IL-4, IL-10 or TNF-alpha, and proposed that its antiviral effect works by shifting the Th1/Th2/Treg cytokine balance rather than by acting on the virus directly.

Important caveats, stated plainly: this is a 2009 animal and in-vitro study, published in a Russian-language virology journal, and we could find no independent replication outside that research group. "Induced interferon gene expression in mice" is not "will help you fight off a cold".

Thirty-four genes moved — in a mouse spleen

A second line of work took a broader look. Kolomin and colleagues profiled 84 inflammation-related genes — chemokines, cytokines and their receptors — in mouse spleen at 6 and 24 hours after a single Selank injection, and reported significant expression changes in 34 of them. A follow-up paper tracked the time course of those shifts.

This is genuine, careful molecular work, and it is the strongest evidence that Selank does something immunologically. It is also, again, mouse spleen tissue, a single dose, and gene expression rather than any clinical outcome. Gene expression changes are a starting hypothesis, not a demonstrated benefit.

What the human Selank evidence actually measured

Here is the crux. Selank's human record consists of three small Russian trials, the most recent from 2015. The best known compared Selank against the benzodiazepine medazepam in 62 patients with generalised anxiety disorder and neurasthenia — 30 on Selank, 32 on medazepam — and reported broadly comparable anxiolytic effect, with additional anti-asthenic activity and without the sedation, muscle relaxation and withdrawal typical of benzodiazepines.

Every one of those endpoints is psychiatric. None of the human trials measured infection rates, antibody titres, interferon levels or any other immune outcome. The mechanistic biomarker they did track was enkephalin-related: the studies noted shortened plasma leu-enkephalin half-life in anxious patients, consistent with earlier work showing Selank inhibits enkephalin-degrading enzymes in plasma with an IC50 around 15 µM.

So the honest summary is a split record. The anxiety claim has small, unreplicated-outside-Russia human data behind it. The immune and antiviral claim has animal and cell-culture data only, with zero human confirmation. Anyone presenting the two as equally established is overreaching.

Is Selank legal in Australia?

Selank is not listed in the Poisons Standard, which means it is unscheduled — a fact often mistaken for approval. It is not. Selank is an unapproved therapeutic good in Australia: it is not on the Australian Register of Therapeutic Goods, so it cannot lawfully be supplied or advertised here as a therapeutic product, and any immune or antiviral claim made about it in a commercial setting would be an unapproved therapeutic claim on top of that.

Its only national registration anywhere is in Russia, for mild anxiety. That registration does not extend to immune or antiviral indications, despite the preclinical work described above.

For athletes: Selank is not named on the WADA 2026 Prohibited List. The catch-all S0 "non-approved substances" category targets substances with no approval from any government health authority for human use, and Selank's Russian registration makes its S0 position arguable rather than settled. Competing athletes should check directly with Sport Integrity Australia rather than assume.

What would actually move the evidence forward

A single adequately powered, independently run human trial — anywhere — would do more for Selank's credibility than another decade of mouse spleen assays. For the immune claim specifically, the bar is a controlled human study with a hard endpoint: infection incidence, symptom duration, or a validated immune biomarker. Nothing of that kind has been published.

Until then, the accurate framing is that Selank is an immune-derived peptide with interesting preclinical immunology, a thin human anxiety file that stops in 2015, and no approved use in Australia.

Want the evidence-first read on peptide research as it lands? Join the free updates list.

FAQ

What is Selank used for?

Selank is registered only in Russia, for mild anxiety. Its wider research record also covers antiviral and immune-modulating effects, but that work is animal and cell-culture only and has no human confirmation.

Does Selank boost the immune system?

Animal studies report interferon-alpha gene induction and changes in 34 of 84 inflammation-related genes in mouse spleen. No published human trial has measured any immune outcome, so an immune benefit in people remains unproven.

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard, but it is an unapproved therapeutic good — not on the ARTG, and not lawfully supplied or advertised as a therapeutic product in Australia.

Is Selank banned in sport?

Selank is not named on the WADA 2026 Prohibited List. Its status under the S0 non-approved-substances catch-all is arguable given its Russian registration, so athletes should confirm with Sport Integrity Australia.

Sources

This article is information only, not medical advice. retatrutide.net.au is independent and does not sell peptides. Selank is an unapproved therapeutic good in Australia and is not approved by the TGA for any use.